Edition:
United States

OncoTherapy Science Inc (4564.T)

4564.T on Tokyo Stock Exchange

253JPY
29 Mar 2017
Change (% chg)

¥2 (+0.80%)
Prev Close
¥251
Open
¥248
Day's High
¥254
Day's Low
¥245
Volume
846,000
Avg. Vol
1,107,483
52-wk High
¥378
52-wk Low
¥220

Latest Key Developments (Source: Significant Developments)

OncoTherapy Science announces change of president
Sunday, 26 Feb 2017 09:57pm EST 

OncoTherapy Science Inc <4564.T> : Says co appoints Kazuo Yamamoto as new president, replacing Masaharu Mori who resigns .Change will be effective on Feb. 27.  Full Article

OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167
Friday, 15 Jul 2016 03:33am EDT 

OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.  Full Article

OncoTherapy Science gets patent license
Monday, 16 May 2016 04:38am EDT 

OncoTherapy Science Inc <4564.T>: Says received a patent license in China .Says the patent is for specific inhibitor of TOPK (T-LAK cell-originated protein kinase), which being developed as an anti-cancer agent.  Full Article

OncoTherapy Science announces trial result of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma
Tuesday, 22 Mar 2016 07:30pm EDT 

OncoTherapy Science Inc:Announces the positive results of the primary objectives which were safety and bio-distribution were confirmed from Phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma conducted in France.  Full Article

OncoTherapy Science announces positive trial result of phase I/II clinical study of OTSGC-A24
Monday, 21 Mar 2016 10:30pm EDT 

OncoTherapy Science Inc:Announces positive trial result of phase I/II clinical study of carcinoma peptide vaccine cocktail OTSGC-A24 for the treatment of gastric cancer, in Singapore, Korea and Japan.  Full Article

OncoTherapy Science announces positive trial result of phase I clinical study of MELK inhibitor OTS167
Wednesday, 16 Mar 2016 07:30pm EDT 

OncoTherapy Science Inc:Announces positive trial result of phase I clinical study of MELK inhibitor OTS167 in Australia.Says the clinical study turns out good oral absorption properties of OTS167.  Full Article

OncoTherapy Science announces completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’
Sunday, 21 Feb 2016 06:30pm EST 

OncoTherapy Science Inc:Says the phase I clinical study of the anti-cancer therapeutic antibody against synovial sarcoma ‘OTSA101’ has been completed.  Full Article

OncoTherapy Science to start Phase I/II clinical study of OTS167 in USA
Monday, 25 Jan 2016 09:30pm EST 

OncoTherapy Science Inc:Announces commencement of Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA).  Full Article

OncoTherapy Science MELK inhibitor, OTS167, Phase I/II clinical study commencement in U.S
Sunday, 24 Jan 2016 09:30pm EST 

OncoTherapy Science Inc:Says FDA has approved the commencement of Phase I/II clinical study of MELK inhibitor, OTS167, for acute myeloid leukemia.  Full Article

OncoTherapy Science announces patent registration for TOPK-specific inhibitors in Japan
Sunday, 27 Dec 2015 06:30pm EST 

OncoTherapy Science Inc:Announces that OncoTherapy was approved a substance patent in Japan for the TOPK (T-LAK cell-originated protein kinase) -specific inhibitors that are being developed by OncoTherapy as anti-cancer drugs.Patent No. 5849302.  Full Article

More From Around the Web

BRIEF-OncoTherapy Science announces change of president

* Says co appoints Kazuo Yamamoto as new president, replacing Masaharu Mori who resigns